Cedars-Sinai and nference partner to advance multimodal clinical data research

nference today announced a long-term strategic collaboration with Cedars-Sinai to establish a secure platform that will help investigators analyze de-identified and multimodal clinical data. These data sets represent decades of patient care and aim to accelerate the pace of scientific innovation while amplifying research creativity.

Understanding health and disease requires connecting what is happening across organs, across clinical modalities, and across decades of each patient's medical journey. We are building a distinctive foundation for whole-body spatial intelligence to enable triangulation across disparate and unstructured modalities, so that even the most ambitious scientific questions may become more rapidly tractable and result in creative solutions for serving patients worldwide."

Venky Soundararajan, Ph.D., Founder and co-CEO of nference

nference will architect the platform using its federated software that protects patient privacy, harmonizes multimodal data, and supports longitudinal curation with physician-adjudication. The nference technology transforms holistic clinical care information into rigorous research-ready data across all therapeutic, diagnostic and surgical areas. The platform will synthesize insights from all available de-identified modalities including clinical notes, laboratory results, medications, diagnostic reports, radiology and pathology imaging, genomic information, patient-consented biospecimen, electrophysiology waveforms, vitals and flowsheets. With more than a decade of longitudinal records from over 5 million patients, and frequent data refreshes as their routine care progresses over time, this "living" knowledge kernel is envisioned to help researchers gain finer-grained resolution into the inception and progression of diseases.

"We expect this collaboration with nference will provide our clinicians and scientists with new ways to learn from the collective experience of patient care, help validate scientific hypotheses and accelerate biomedical discovery," said Sumeet Chugh, MD, vice dean and chief artificial intelligence health research officer at Cedars-Sinai.

The platform is intended to support investigator-led studies, grant-funded research, education, quality improvement and collaboration with life science industry partners. It will also provide a foundation for Cedars-Sinai researchers and affiliated innovators to develop and evaluate new AI models, with the potential to inform drug discovery, clinical trial design and future diagnostics.

Source:

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Submicron IR for pharmaceutical research, development, and quality